AB 463 — Pharmaceutical Cost Transparency Act of 2016.
Last action — From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
-
✓Introduced
-
2In Committee
-
3Passed Assembly
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill died with 2015-2016 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Existing law establishes the Office of Statewide Health Planning and Development, which is vested with all the duties, powers, responsibilities, and jurisdiction of the State Department of Public Health relating to health planning and research development. This bill would require each manufacturer of a prescription drug, made available in California, that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment to file a report, no later than May 1 of each year, with the Office of Statewide Health Planning and Development on the costs for each qualifying drug, as specified. The bill would require the office to issue a report annually to the Legislature outlining the information submitted pursuant to the bill and to post the report on its Internet Web site. The bill would also require the office to convene an advisory workgroup, as provided, to develop the reporting form required by this bill. The bill would require the office to maintain the confidentiality of any information submitted by a prescription drug manufacturer pursuant to those provisions that the director of the office deems to be confidential and proprietary. Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest. This bill would make legislative findings to that effect.
Bill Text
- Amended 01/04/16 - Amended Assembly Current pdf January 04, 2016
- Introduced 02/23/15 - Introduced pdf February 23, 2015
- AB463 View text html
Action History
-
From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
-
Died pursuant to Article IV, Sec. 10(c) of the Constitution.
-
In committee: Set, second hearing. Hearing canceled at the request of author.
-
Re-referred to Com. on HEALTH.
-
From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
-
In committee: Hearing postponed by committee.
-
In committee: Set, first hearing. Hearing canceled at the request of author.
-
Referred to Com. on HEALTH.
-
From printer. May be heard in committee March 26.
-
Read first time. To print.
Sponsors
- Chiu · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 121 not signed on
Sponsors (1)
- Chiu
Co-sponsors (0)
None.
Not signed on (121)
121 members have not signed on to this bill.
Show all 121 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does AB 463 do?
- Existing law establishes the Office of Statewide Health Planning and Development, which is vested with all the duties, powers, responsibilities, and jurisdiction of the State Department of Public Health relating to health planning and research development. This bill would require each manufacturer of a prescription drug, made available in California, that has a wholesale acquisition cost of $10,000 or more annually or per course of treatment to file a report, no later than May 1 of each year, with the Office of Statewide Health Planning and Development on the costs for each qualifying drug, as specified. The bill would require the office to issue a report annually to the Legislature outlining the information submitted pursuant to the bill and to post the report on its Internet Web site. The bill would also require the office to convene an advisory workgroup, as provided, to develop the reporting form required by this bill. The bill would require the office to maintain the confidentiality of any information submitted by a prescription drug manufacturer pursuant to those provisions that the director of the office deems to be confidential and proprietary. Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest. This bill would make legislative findings to that effect.
- Who sponsors AB 463?
- AB 463 is sponsored by Chiu.
- What is the current status of AB 463?
- This bill died with 2015-2016 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track AB 463?
- Track AB 463 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on AB 463
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of AB 463
Last checked for changes 2 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →